FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912941354> ?p ?o ?g. }

• W2912941354 endingPage "4365" @default.
• W2912941354 startingPage "4365" @default.
• W2912941354 abstract "Abstract Introduction. The association of Azacitidine (AZA) and Lenalidomide (LEN), either administered concurrently (Sekeres, 2010; 2012; 2017), or sequentially (Platzbecker, 2013; Di Nardo 2015; Mittelman 2016; Narayan 2016) has proven effective in Myelodysplastic Syndromes (MDS), however the optimum dose and schedule remains unknown. The aim of this study was to evaluate the efficacy and safety of the combination vs the sequential use of AZA and LEN in higher-risk MDS pts. Primary endpoint: ORR, defined as the Rate of Complete Remission (CR), Partial Remission (PR), Marrow Complete Remission (mCR), and Hematological Improvement (HI), following the IWG criteria (Cheson, 2006). Secondary endpoints: a) rate of CR; b) duration of responses; c) overall survival (OS). Methods. This is a randomized, phase II, multicenter, open label study, including pts with MDS with IPSS risk High or Intermediate-2, without previous treatment with AZA or LEN. ARM 1 (combined treatment): AZA: 75 mg/m2/day (days 1-5) I.C. + LEN: 10 mg/day (days 1-21), orally, every 4 weeks. ARM 2 (sequential treatment): AZA: 75 mg/m2/day (days 1-5) I.C. + LEN: 10 mg/day (days 6-21), orally, every 4 weeks. The induction treatment was planned for 8 cycles. For responder patients the same treatment was continued until disease progression or unacceptable toxicity. Results. From March 2013, 44 pts (27 males), median age: 72 (48-83 yrs) were enrolled, from 13 hematologic Centers. At baseline, IPSS risk was: Intermediate-2: 31 pts; High: 9 pts; not determined (N.D.) (because of lack of cytogenetic data): 2 pts. (all with RAEB-2). In 2 pts IPSS risk was Intermediate-1, but they were enrolled because of severe thrombocytopenia and neutropenia, respectively. IPSS-R risk was: intermediate: 8 pts; High: 16 pts; Very-High: 18 pts; N.D.: 2 pts. In 5 pts (11.4%) del(5q) was present (additional cytogenetic alterations: 1 in 1 pt, and > 1 in 4 pts , respectively). 21 pts were randomly assigned to ARM 1, and 23 pts to ARM 2. Treatment was given for a median of 8.5 (1-52) cycles; in ARM 1: 9 (1-51) cycles; in ARM 2: 8 (1-52) cycles, respectively. Median follow-up: 15 (2-54) months; 47 (37-54) months for survivors. 10/44 pts (22.7%) did not complete at least 6 cycles of treatment for causes other than disease progression (6 pts for adverse events, 2 pts for consent withdrawal and 2 pts for medical decision), and were not considered evaluable for response. Among the 34/44 pts (77.3%) evaluable for response, 26/34 pts (ORR: 76.5 %) showed a favourable response to treatment. Intention-to-treat (ITT) analysis: ORR: 59.1%. First response was observed after a median of 2 (1-8) cycles. The Best Response achieved was: CR: 8 pts (23.5%) (ITT: 18.1%), PR: 1 pt (2.9%) (ITT: 2.2%), mCR: 3 pts (8.8%) (ITT: 6.8%), HI: 8 pts (23.5%) (ITT: 18.1%), mCR+HI: 6 pts (17.6%) (ITT: 13.6%). The remaining 8 pts showed either Stable Disease (SD) (6 pts, 17.6%) or Disease Progression (DP) (2 pts, 5.9%). Among the 27 pts (21 evaluable for response) with an abnormal karyotype at baseline, ORR was 66.7% (ITT: 51.8%) and 4 pts achieved complete cytogenetic response. Median duration of hematologic response: 10.5 months. 34 pts (77,3%) died , and 17 pts (38.6%) showed progression to AML. Grade >2 non haematological toxicity: 54.5%. Median OS: 15 months. No significant differences between the 2 arms were observed, in terms of ORR (ARM 1: 76.5%, ITT: 61.9%; ARM 2: 76.5%, ITT: 56.5%), CR rate (ARM 1: 17.6%, ITT: 14.3%; ARM 2: 29.4%, ITT: 21.7%), grade >2 non haematological toxicity (ARM 1: 66.7%; ARM 2: 43.5%), AML incidence (ARM 1: 28.6%; ARM 2: 47.8%) and OS (ARM 1: 14 months; ARM 2: 16 months), but the median response duration was significantly longer in ARM 2 (18 months) as compared to ARM 1 (6 months) (p=0.0459). At the time of last analysis, 5/44 (11.4%) patients, 1/21 (4.8%) in ARM 1, and 4/23 (17.4%) in ARM 2, were still maintaining the haematological response, and were still in treatment, after 54, 54, 52, 51 and 37 months, and after 52, 51, 33, 48 and 35 cycles of therapy, respectively. The changes observed during treatment in mutational status of inositide-specific genes and microRNA expression profiling were related to clinical outcome, predicting a negative response to therapy. Conclusions. Our results confirm the efficacy of both AZA+LEN treatment regimens in higher-risk MDS pts, in terms of ORR and OS, although pts treated with the sequential regimen showed a significantly longer duration of haematological response. Disclosures Finelli: Celgene: Other: speaker fees, Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: speaker fees; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: speaker fees. Candoni:Janssen: Honoraria, Speakers Bureau; Celgene: Honoraria, Speakers Bureau; Gilead: Honoraria, Speakers Bureau; Pfizer: Honoraria, Speakers Bureau; Merck SD: Honoraria, Speakers Bureau. Gobbi:Novartis: Consultancy; Janssen: Consultancy; Ariad: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy; Pfister: Membership on an entity's Board of Directors or advisory committees. Rigolin:Gilead: Research Funding. Cavo:GlaxoSmithKline: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees." @default.
• W2912941354 created "2019-02-21" @default.
• W2912941354 creator A5003619706 @default.
• W2912941354 creator A5006854942 @default.
• W2912941354 creator A5007706683 @default.
• W2912941354 creator A5008040655 @default.
• W2912941354 creator A5013622378 @default.
• W2912941354 creator A5014739728 @default.
• W2912941354 creator A5019461184 @default.
• W2912941354 creator A5024215041 @default.
• W2912941354 creator A5031970751 @default.
• W2912941354 creator A5033434550 @default.
• W2912941354 creator A5035912933 @default.
• W2912941354 creator A5036055911 @default.
• W2912941354 creator A5037637576 @default.
• W2912941354 creator A5042328462 @default.
• W2912941354 creator A5046121522 @default.
• W2912941354 creator A5070851212 @default.
• W2912941354 creator A5071926851 @default.
• W2912941354 creator A5078922292 @default.
• W2912941354 creator A5083873250 @default.
• W2912941354 creator A5086068112 @default.
• W2912941354 creator A5091833370 @default.
• W2912941354 date "2018-11-29" @default.
• W2912941354 modified "2023-09-30" @default.
• W2912941354 title "Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined versus Sequential) in Higher-Risk Myelodysplastic Syndromes. Update of Long-Term Results of a Randomized Phase II Multicenter Study" @default.
• W2912941354 doi "https://doi.org/10.1182/blood-2018-99-117714" @default.
• W2912941354 hasPublicationYear "2018" @default.
• W2912941354 type Work @default.
• W2912941354 sameAs 2912941354 @default.
• W2912941354 citedByCount "1" @default.
• W2912941354 countsByYear W29129413542020 @default.
• W2912941354 crossrefType "journal-article" @default.
• W2912941354 hasAuthorship W2912941354A5003619706 @default.
• W2912941354 hasAuthorship W2912941354A5006854942 @default.
• W2912941354 hasAuthorship W2912941354A5007706683 @default.
• W2912941354 hasAuthorship W2912941354A5008040655 @default.
• W2912941354 hasAuthorship W2912941354A5013622378 @default.
• W2912941354 hasAuthorship W2912941354A5014739728 @default.
• W2912941354 hasAuthorship W2912941354A5019461184 @default.
• W2912941354 hasAuthorship W2912941354A5024215041 @default.
• W2912941354 hasAuthorship W2912941354A5031970751 @default.
• W2912941354 hasAuthorship W2912941354A5033434550 @default.
• W2912941354 hasAuthorship W2912941354A5035912933 @default.
• W2912941354 hasAuthorship W2912941354A5036055911 @default.
• W2912941354 hasAuthorship W2912941354A5037637576 @default.
• W2912941354 hasAuthorship W2912941354A5042328462 @default.
• W2912941354 hasAuthorship W2912941354A5046121522 @default.
• W2912941354 hasAuthorship W2912941354A5070851212 @default.
• W2912941354 hasAuthorship W2912941354A5071926851 @default.
• W2912941354 hasAuthorship W2912941354A5078922292 @default.
• W2912941354 hasAuthorship W2912941354A5083873250 @default.
• W2912941354 hasAuthorship W2912941354A5086068112 @default.
• W2912941354 hasAuthorship W2912941354A5091833370 @default.
• W2912941354 hasConcept C104317684 @default.
• W2912941354 hasConcept C126322002 @default.
• W2912941354 hasConcept C141071460 @default.
• W2912941354 hasConcept C150194340 @default.
• W2912941354 hasConcept C168563851 @default.
• W2912941354 hasConcept C185592680 @default.
• W2912941354 hasConcept C190727270 @default.
• W2912941354 hasConcept C197934379 @default.
• W2912941354 hasConcept C202953159 @default.
• W2912941354 hasConcept C203092338 @default.
• W2912941354 hasConcept C2776063141 @default.
• W2912941354 hasConcept C2776239401 @default.
• W2912941354 hasConcept C2776364478 @default.
• W2912941354 hasConcept C2777063308 @default.
• W2912941354 hasConcept C2780007613 @default.
• W2912941354 hasConcept C2780240888 @default.
• W2912941354 hasConcept C2780366003 @default.
• W2912941354 hasConcept C2780817109 @default.
• W2912941354 hasConcept C29730261 @default.
• W2912941354 hasConcept C31760486 @default.
• W2912941354 hasConcept C55493867 @default.
• W2912941354 hasConcept C71924100 @default.
• W2912941354 hasConcept C90924648 @default.
• W2912941354 hasConceptScore W2912941354C104317684 @default.
• W2912941354 hasConceptScore W2912941354C126322002 @default.
• W2912941354 hasConceptScore W2912941354C141071460 @default.
• W2912941354 hasConceptScore W2912941354C150194340 @default.
• W2912941354 hasConceptScore W2912941354C168563851 @default.
• W2912941354 hasConceptScore W2912941354C185592680 @default.
• W2912941354 hasConceptScore W2912941354C190727270 @default.
• W2912941354 hasConceptScore W2912941354C197934379 @default.
• W2912941354 hasConceptScore W2912941354C202953159 @default.
• W2912941354 hasConceptScore W2912941354C203092338 @default.
• W2912941354 hasConceptScore W2912941354C2776063141 @default.
• W2912941354 hasConceptScore W2912941354C2776239401 @default.
• W2912941354 hasConceptScore W2912941354C2776364478 @default.
• W2912941354 hasConceptScore W2912941354C2777063308 @default.
• W2912941354 hasConceptScore W2912941354C2780007613 @default.
• W2912941354 hasConceptScore W2912941354C2780240888 @default.
• W2912941354 hasConceptScore W2912941354C2780366003 @default.
• W2912941354 hasConceptScore W2912941354C2780817109 @default.
• W2912941354 hasConceptScore W2912941354C29730261 @default.
• W2912941354 hasConceptScore W2912941354C31760486 @default.
• W2912941354 hasConceptScore W2912941354C55493867 @default.

• next